Detection of Mycobacterium avium ss. Paratuberculosis in Blau Syndrome Tissues by Dow, C. Thomas & Ellingson, Jay L. E.
SAGE-Hindawi Access to Research
Autoimmune Diseases




in Blau Syndrome Tissues
C.Thomas Dow1,2 and JayL. E. Ellingson3
1Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, 600 Highland Avenue,
Madison, WI 53792, USA
2Chippewa Valley Eye Clinic, 2715 Damon Street, Eau Claire, WI 54701, USA
3Kwik Trip Inc., 2302 Kwik Trip Way, La Crosse, WI 54602, USA
Correspondence should be addressed to C. Thomas Dow, ctd@discover-net.net
Received 2 January 2010; Revised 1 May 2010; Accepted 11 May 2010
Academic Editor: Edmond J. Yunis
Copyright © 2010 C. T. Dow and J. L. E. Ellingson. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background and Aim of the Work. Blau syndrome is an inherited granulomatous inﬂammatory disorder with clinical ﬁndings of
uveitis, arthritis, and dermatitis. Although rare, Blau syndrome shares features with the more common diseases sarcoidosis and
Crohn’s disease. The clinical ﬁndings of Blau syndrome are indistinguishable from juvenile sarcoidosis; the mutations of Blau
syndrome are on the same gene of chromosome 16 (CARD15) that confers susceptibility to Crohn’s disease. The product of this
gene is part of the innate immune system. Mycobacterium avium ss. paratuberculosis (MAP) is the putative cause of Crohn’s disease
andhasbeenimplicatedasacausativeagentofsarcoidosis.Methods.ArchivaltissuesofindividualswithBlausyndromeweretested
for the presence of MAP. Results. DNA evidence of MAP was detected in all of the tissues. Conclusions. This article ﬁnds that MAP
is present in Blau syndrome tissue and postulates that it has a causal role. The presence of MAP in Blau syndrome—an autosomal
dominant, systemic inﬂammatory disease—connects genetic and environmental aspects of “autoimmune” disease.
1.Introduction
Blau syndrome is familial juvenile systemic granulomatosis
[1]. Although rare, Blau syndrome has been of interest
in current medical literature because of the discovery that
places its genetic defect on the same gene as one of the
susceptibilitygenesforCrohn’sdisease[2,3].Linkagestudies
have placed the gene on chromosome 16; originally referred
to as the NOD2 gene, it is now known as the CARD15
gene [4]. The Blau syndrome susceptibility component of
the CARD15 gene is at the nucleotide binding site domain
[2, 5] while the Crohn’s susceptibility is at the N-terminal
leucine-rich repeat domain [4, 6]. In addition to Crohn’s
disease and Blau syndrome, mutations of the CARD15 gene
have been linked to psoriatic arthritis [7]. The CARD15
gene is part of the ancestral innate immune system that
senses and eliminates bacteria [8, 9], and is part of the newly
recognized, larger CATERPILLER gene family which acts as
sensors to detect pathogens which regulates inﬂammatory
and apoptotic responses [10]. Blau syndrome is unique in
that it is the only systemic granulomatous disease that has
a recognized Mendelian pattern of inheritance: autosomal
dominant [11]. The landmark progress associating this
gene with systemic granulomatous disease has prompted
studies of other granulomatous disease to look for a similar
defect [3, 12]. While CARD15 defects confer susceptibility
Crohn’s disease, Blau syndrome, and psoriatic arthritis [7]
no such defects were found in patients with sarcoidosis [13],
ankylosing spondylitis [14] Wegener’s granulomatosis [15],
systemic lupus erythematosus [16], or rheumatoid arthritis
[17].
Mycobacterium avium ss. paratuberculosis (MAP) is an
obligate intracellular organism that causes an enteric gran-
ulomatous disease in ruminant animals, Johne’s disease [18,
19]. MAP is the putative cause of Crohn’s disease, a similar
enteric granulomatous disease of humans [20–24].
Traditional methods of detecting bacteria, culture, and
stain, are largely ineﬀective in detecting MAP in humans.2 Autoimmune Diseases
Table 1: Results of DNA probing for IS900 and hpsX of Mycobacterium avium ss. paratuberculosis (MAP) in Blau Syndrome tissues.
Source Rose [36] DeChadarevian [37] Ziegler [38]
Patient Mother Child Both tissues from same patient Mother Child
Tissue Liver Synovium Synovium Skin Kidney Skin
IS900 + ++ + + +
hspX ++ +
Gel Lanes 2,3,4 56 7 8,9,10 11
The bacteria are very diﬃcult to culture and MAP is
able to exist in a spheroplast (cell wall deﬁcient) form in
humans [25–27]. The advent of bacterial DNA detection
with polymerase chain reaction (PCR) has greatly aided
the detection of mycobacteria [28, 29]. In one series, the
DNA of MAP was identiﬁed in greater than 90% of biopsy
specimens fromindividuals with Crohn’s disease [30]. Viable
MAP has been recovered from the blood of patients with
Crohn’s disease [31]. Yet, the diﬃculty in culturing MAP
from the blood of individuals with Crohn’s is evident in a
recent paper by Parrish [32] in which no samples grew MAP
and, in another recent paper successful recovery of MAP
was achieved in split samples [33]. In addition to Crohn’s
disease, MAP is also implicated in sarcoidosis [34]. Because
of the association of Blau syndrome with the gene conferring
susceptibility to Crohn’s disease and because clinical ﬁndings
of Blau syndrome are evocative of juvenile sarcoidosis, we
postulated that MAP might play a role in Blau syndrome.
Tissues were tested for MAP with DNA probes for IS900 and
hspX. IS900 is a multicopy genetic element and is a standard
probe for MAP, and hspX is very speciﬁc as it probes for a
single gene speciﬁc to MAP [35].
2.MaterialsandMethods
Several clinicians who had published articles that included
Blau syndrome granulomas were contacted and solicited
to send representative samples for DNA probing for MAP.
Three authors sent tissues: paraﬃn blocks of Blau skin,
synoviumandlivergranulomas[36,37],andunstainedslides
of Blau skin and renal granulomas [38]. Six diﬀerent tissues
from ﬁve patients representing three kindred were received
and subjected to DNA probe for MAP. IS900 is the most
commonly recognized DNA sequence associated with MAP
and has multiple copies within the genome [18, 39]. An
additional element has been found, hspX; this marker is
more speciﬁc for MAP as there is only one copy within the
MAP genome [35].
Tissues mounted on slides were prepared as follows: each
tissue section was scraped from the glass slide into a sterile
microcentrifuge tube using a sterile scalpel. Sections of the
same tissue from diﬀerent slides were pooled. Patient tissues
embedded in paraﬃn were prepared as follows: blocks were
eﬀaced until complete tissue sections were obtained, then
ﬁve, 5-micron sections of each paraﬃn-embedded tissue was
cutandplacedintoasterilemicrocentrifugetube.Tris-EDTA
(TE) buﬀer (100μL; pH 7.5) was then added to each tissue
sample and vortexed for 1 minute. The tubes containing
samples were then placed into a boiling water bath for 10
minutes and then immediately vortexed for 2 minutes. The
10-minute boiling step followed by 2 minutes of vortexing
was repeated twice (a total of 3 times). Tubes were boiled for
an additional 5 minutes, cooled to room temperature and
then centrifuged at 10,000rpm’s for 10 minutes. DNA was
extracted from 100μL of the supernatant using the Magna
Pure LC DNA Isolation Kit III (Roche Diagnostics Corpo-
ration, Indianapolis, IN) according to the manufacturer’s
instructions.DNAwasampliﬁedaccordingtotheparameters
described by Miller et al. (1999). Ampliﬁed PCR reactions
were analyzed by agarose gel electrophoresis (1.5% agarose
gel). All products were compared to a standard molecular
weightladderandthepositivecontroltodetermineamplicon
size. A sample was considered positive if ampliﬁed product
was noted at 229bp for the IS900 primer set and 211bp with
the hspX primer set. (Testing was performed by the Food
Services Laboratory at the Marshﬁeld Clinic, Marshﬁeld,
Wisconsin.) Polymerase chain reaction (PCR) [40].
3. Results
The tested tissues represented six archival samples of Blau
syndrome pathologic specimens. They were from ﬁve dif-
ferent patients and represented three diﬀerent kindred. All
tissues tested positive for IS900. Three tissues tested positive
for the hspX. (Table 1 and Figure 1).
4. Discussion
In addition to the historic interest of MAP in Crohn’s and
sarcoidosis, there is recent interest in MAP as an immune
trigger of several autoimmune diseases [41–43]. Increasing
evidence suggests a role for MAP in autoimmune (Type
1) diabetes. It is postulated that MAP acts via molecular
mimicry between genetic elements of MAP (HSP65) and the
pancreatic enzyme glutamic acid decarboxylase (GAD) [44–
48]. The presence of MAP DNA in Blau syndrome tissues
was postulated because of the genetic connection to Crohn’s
diseaseandbecauseofitsclinicalsimilaritiestosarcoidosis—
both diseases associated with MAP. Recent studies have
demonstrated that sporadic cases of “juvenile sarcoidosis”
are instead de novo CARD15 defects associated with Blau
syndrome [49, 50]. This article postulates the CARD15
defect associated with Blau syndrome allows for a persistentAutoimmune Diseases 3
hspX
IS900
123456 789 1 0 1 1 1 2 1 3 1 4
Figure 1: top—IS900, bottom—hspX. LANE 1 100bp ladder 2–
11 See Table 1. 12 Positive control MAP-ATCC 19698 13 Negative
control 14 100bp ladder.
presence of MAP. The presence of MAP in Blau syndrome-
an autosomal dominant, systemic, inﬂammatory disease-
connects genetic, and environmental (infectious) aspects of
“autoimmune”disease.LargerscalestudiesofBlausyndrome
individuals will need to be completed and include testing
for MAP bacteremia to further elucidate the roll of this
intriguing pathogen.
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